MannKind Corp (NASDAQ:MNKD)

buy sell

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

Stocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors have to decide whether the next year or more will ...
Read Full Story »
MannKind Poll smaller

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

MannKind Corp. (NASDAQ: MNKD) has dipped back under $10 in the wake of the FDA finally giving approval for its Afrezza as inhalable insulin for diabetic patients. The move may ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

Stocks were firm on Tuesday morning during a shortened week that will be full of economic reports. 24/7 Wall St. reviews dozens of analyst research reports each morning of the ...
Read Full Story »
76764023

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

MannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 ...
Read Full Story »
biotech

Vindication for MannKind on FDA Approval

After markets closed last Friday, MannKind Corp. (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control ...
Read Full Story »
biotech

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

The U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The ...
Read Full Story »
buy sell

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

Stocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the ...
Read Full Story »
76764023

The MannKind Lifeline Lights Up

MannKind Corp. (NASDAQ: MNKD) could have been and should have been featured in our Analyst Stocks to Buy Under $10 For Huge Upside this weekend, but MannKind is such a ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More

It is Friday (the 13th, mind you) and stocks are trying to find direction after a couple of big selling days this week. Investors keep hearing that the raging bull market ...
Read Full Story »
biotech

Short Sellers Remain Vigilant Against Top Biotech Stocks

Short sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company ...
Read Full Story »
ten bucks

Twelve Analyst Stocks to Buy Under $10 for Big Upside

Stocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7 Wall St. reviews dozens of analyst research reports from Wall ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Akamai, Avago, MannKind, Pandora, Randgold and More

With the Dow Jones Industrial Average and S&P 500 hitting new all-time highs, investors want upside but they also want to avoid the next trap. Market pundits and portfolio managers ...
Read Full Story »
biotech

Companies Betting on the Next 10 Blockbuster Drugs

The biotech sector has seen its valuations hit hard in many cases in 2014, but many investors remain excited about the future wave of big biotech drugs -- and big ...
Read Full Story »
Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
stock symbol ticker

The 4 Stocks That Rescued the Rally for One More Day

April 2, 2014: Markets opened mixed on Wednesday following in the ADP payroll data and n increase in factory orders reported early in the day. Mortgage applications were down again ...
Read Full Story »